Utility of Aripiprazole in the Treatment of Anorexia Nervosa in Children and Adolescents: A Retrospective, Descriptive, Matched Cohort Study
Journal of Child and Adolescent Psychopharmacology · 2025
DOI: 10.1089/cap.2025.0013 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, 2025. Verfasst von Isabelle Bindseil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Aripiprazole, Anorexia Nervosa, Antipsychotic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
Current standards for treatment of anorexia nervosa (AN) in children and adolescents include Family-Based Treatment and nutrition restoration. The use of aripiprazole for AN has been detailed through case series and one retrospective review analyzing the change in outcomes on body mass index and weight restoration. The goal of this descriptive study was to evaluate the impact of aripiprazole on food avoidant behaviors (FABs) and to describe prescribing patterns, including dosing and tolerability.
Methods
This was a retrospective, descriptive, matched, cohort study of pediatric patients with AN admitted to an eating disorders program (EDP) between January 1, 2018, and December 31, 2023. Patients were included in this study if they had a diagnosis of AN and were started on aripiprazole for eating disorder cognitions. Patients were matched 1:2 to a control group based on age, sex, and length of stay.
Results
A total of 42 patients on aripiprazole were analyzed and matched to 84 controls. Aripiprazole was associated with a reduction in FABs with a mean change over the evaluated time period of 3.5 versus 0.9 ( p = 0.026). The mean starting dose of aripiprazole was 1.9 mg/day, with a mean discharge dose of 2.8 mg/day. Aripiprazole was overall well-tolerated.
Conclusion
Aripiprazole was associated with an improvement in FABs among children and adolescents admitted to an EDP. Additionally, low-dose aripiprazole improved weight, likelihood of achieving target weight, and was well-tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Children's Hospital Colorado, Aurora, Colorado, USA.
- Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
- Pediatric Mental Health Institute, Children's Hospital Colorado, Aurora, Colorado, USA.
- Child and Adolescent Mental Health Division, Department of Psychiatry at the University of Colorado School of Medicine, Aurora, Colorado, USA.
ORCID-Profile: Isabelle Bindseil, Danielle L Stutzman
Zitieren
APA
Bindseil, I., Stutzman, D. L., Schiel, M. A., Sheffield, K., & Hagman, J. (2025). Utility of Aripiprazole in the Treatment of Anorexia Nervosa in Children and Adolescents: A Retrospective, Descriptive, Matched Cohort Study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/cap.2025.0013
Vancouver
Bindseil I, Stutzman DL, Schiel MA, Sheffield K, Hagman J. Utility of Aripiprazole in the Treatment of Anorexia Nervosa in Children and Adolescents: A Retrospective, Descriptive, Matched Cohort Study. Journal of Child and Adolescent Psychopharmacology. 2025. doi:10.1089/cap.2025.0013
BibTeX
@article{Bindseil2025,
author = {Bindseil, Isabelle and Stutzman, Danielle L and Schiel, Marissa A and Sheffield, Kimberly and Hagman, Jennifer},
title = {Utility of Aripiprazole in the Treatment of Anorexia Nervosa in Children and Adolescents: A Retrospective, Descriptive, Matched Cohort Study},
journal = {Journal of Child and Adolescent Psychopharmacology},
year = {2025},
doi = {10.1089/cap.2025.0013}
}
EUVIMED